Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Glod

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 25, 2021
Catastrophic ATP loss underlies a metabolic combination therapy tailored for <i>MYCN</i>-amplified neuroblastomaKrista M Dalton, Timothy L Lochmann, Konstantinos V Floros, et al.
Cancer Research|January 23, 2021
<i>MYCN</i>-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione AxisKonstantinos V Floros, JinYang Cai, Sheeba Jacob, et al.
JCO Precision Oncology|June 8, 2026
Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid CarcinomaDavid Milewski, Arwa Fallatah, Maya Groff, et al.
Sarcoma|May 14, 2020
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the LungKristin Baird, John Glod, Seth M Steinberg, et al.
The New England Journal of Medicine|December 29, 2016
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform NeurofibromasEva Dombi, Andrea Baldwin, Leigh J Marcus, et al.
Journal of Neuro-Oncology|October 11, 2020
A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomasSean J Hipp, Stewart Goldman, Aradhana Kaushal, et al.
Nature Communications|September 8, 2022
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcomaAlexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, et al.
Cancer Discovery|June 13, 2018
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 <sup>c259</sup>T Cells in Synovial SarcomaSandra P D'Angelo, Luca Melchiori, Melinda S Merchant, et al.
Journal for Immunotherapy of Cancer|October 26, 2019
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcomaIndu Ramachandran, Daniel E Lowther, Rebecca Dryer-Minnerly, et al.
The New England Journal of Medicine|March 19, 2020
Selumetinib in Children with Inoperable Plexiform NeurofibromasAndrea M Gross, Pamela L Wolters, Eva Dombi, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Proceedings of the National Academy of Sciences of the United States of America|March 25, 2021
Catastrophic ATP loss underlies a metabolic combination therapy tailored for <i>MYCN</i>-amplified neuroblastomaKrista M Dalton, Timothy L Lochmann, Konstantinos V Floros, et al.
Cancer Research|January 23, 2021
<i>MYCN</i>-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione AxisKonstantinos V Floros, JinYang Cai, Sheeba Jacob, et al.
JCO Precision Oncology|June 8, 2026
Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid CarcinomaDavid Milewski, Arwa Fallatah, Maya Groff, et al.
Sarcoma|May 14, 2020
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the LungKristin Baird, John Glod, Seth M Steinberg, et al.
The New England Journal of Medicine|December 29, 2016
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform NeurofibromasEva Dombi, Andrea Baldwin, Leigh J Marcus, et al.
Journal of Neuro-Oncology|October 11, 2020
A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomasSean J Hipp, Stewart Goldman, Aradhana Kaushal, et al.
Nature Communications|September 8, 2022
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcomaAlexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, et al.
Cancer Discovery|June 13, 2018
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 <sup>c259</sup>T Cells in Synovial SarcomaSandra P D'Angelo, Luca Melchiori, Melinda S Merchant, et al.
Journal for Immunotherapy of Cancer|October 26, 2019
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcomaIndu Ramachandran, Daniel E Lowther, Rebecca Dryer-Minnerly, et al.
The New England Journal of Medicine|March 19, 2020
Selumetinib in Children with Inoperable Plexiform NeurofibromasAndrea M Gross, Pamela L Wolters, Eva Dombi, et al.
Pageof 6